Importantly, KS-133 is active in vivo, inhibiting VIPR2-mediated CREB activation and preventing cognitive impairment in a pharmacological model of early postnatal VIPR2 overactivation, a relevant mouse model of schizophrenia (Ago et al., 2015; Ago et al., 2021). Here, VIPR2 is linked to Cognitive impairment.